The convergence of new technology platforms (including induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, and advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence, have led to an exciting renaissance of phenotypic drug discovery.
This meeting will integrate academic and industry approaches to PDD, covering evolving advances in new PDD technologies and biological models, across various human disease areas. The program will address critical barriers in the field, including how to improve the physiological relevance of phenotypic models, identifying phenotypic targets and mechanisms of action. Attendees will learn new techniques and tools to advance their research, and the field.
Program Highlights:
Featuring presentations by industry leaders including Genentech, Abbvie, Merck, Novartis and more!